Lindus sheds CRO operations to focus on drug discovery
Lindus Therapeutics, a startup backed by Peter Thiel, is selling its contract research organization arm to concentrate on developing its own drug candidates. The company previously marketed itself as an 'anti-CRO' but is now shifting its business model toward in-house drug development.
Expanded Detail
EXPANDED:
Lindus Therapeutics is divesting its contract research organization (CRO) division, a strategic pivot that prioritizes the advancement of its own proprietary drug pipeline. This move reverses the company's earlier positioning as an "anti-C
Expanded detail and Context are AI-generated analysis; the linked article remains the authoritative source.
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “Thiel-backed Lindus sells CRO arm in pivot to hunt for drug assets.” Browse more stories.